Workflow
AbCellera Biologics Inc. (ABCL) Reports Q4 Loss, Misses Revenue Estimates
ABCLAbCellera Biologics(ABCL) ZACKS·2025-02-28 00:15

Company Performance - AbCellera Biologics Inc. reported a quarterly loss of 0.11pershare,betterthantheZacksConsensusEstimateofalossof0.11 per share, better than the Zacks Consensus Estimate of a loss of 0.15, and an improvement from a loss of 0.17pershareayearago,representinganearningssurpriseof26.670.17 per share a year ago, representing an earnings surprise of 26.67% [1] - The company posted revenues of 5.05 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 40.83%, and down from 9.18millioninthesamequarterlastyear[2]−Overthelastfourquarters,AbCellerahassurpassedconsensusEPSestimatesthreetimesbuthasnotbeatenconsensusrevenueestimates[2]StockOutlook−TheimmediatepricemovementofAbCellera′sstockwilldependonmanagement′scommentaryduringtheearningscallandthecompany′searningsoutlook[3][4]−ThecurrentconsensusEPSestimatefortheupcomingquarteris−9.18 million in the same quarter last year [2] - Over the last four quarters, AbCellera has surpassed consensus EPS estimates three times but has not beaten consensus revenue estimates [2] Stock Outlook - The immediate price movement of AbCellera's stock will depend on management's commentary during the earnings call and the company's earnings outlook [3][4] - The current consensus EPS estimate for the upcoming quarter is -0.18 on revenues of 13.97million,andforthecurrentfiscalyear,itis−13.97 million, and for the current fiscal year, it is -0.71 on revenues of $46.43 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which AbCellera belongs, is currently in the top 28% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact AbCellera's stock performance [5][6]